Professor, Internal Medicine, University of Cincinnati College of Medicine
Oncology
Dr. Elyse E. Lower, MD
|
|
Give Review
Elyse Lower practices Oncology. She went to medical school at University Hospital - University of Cincinnati College of Medicine. She received 3 awards: "Meaningful Use Stage 1 Certification", "Fellow (FACP)" and "Top MD". Doctor Elyse E. Lower, MD is a published physician. She has 91 papers published. The most current publication "Vascularity of proliferative breast disease and carcinoma in situ correlates with histological features." She is registered with Medicare and accepts Medicare payments.
Publications
- Clinical management of pulmonary sarcoidosis.
- Medical therapy of sarcoidosis.
- Frequency of acute worsening events in fibrotic pulmonary sarcoidosis patients.
- Established and experimental medical therapy of pulmonary sarcoidosis.
- Endpoints for clinical trials of sarcoidosis.
- Armodafinil for Sarcoidosis-Associated Fatigue: A Double-Blind, Placebo-Controlled, Crossover Trial.
- Management of ocular sarcoidosis.
- Efficacy and Safety of Apremilast in Chronic Cutaneous Sarcoidosis.
- Bone health issues in sarcoidosis.
- Who dies from sarcoidosis and why?
- Survival in sarcoidosis-associated pulmonary hypertension: the importance of hemodynamic evaluation.
- Quality of life in sarcoidosis: assessment and management.
- Ocular sarcoidosis.
- Efficacy of dexmethylphenidate for the treatment of fatigue after Cancer chemotherapy: a randomized clinical trial.
- Fatigue in sarcoidosis: a Systematic review.
- Double-blind, randomized trial of dexmethylphenidate hydrochloride for the treatment of sarcoidosis-associated fatigue.
- Six-minute walk test in managing and monitoring sarcoidosis patients.
- Six-minute walk test and health status assessment in sarcoidosis.
- Evidence-based therapy for cutaneous sarcoidosis.
- Evaluation of fulvestrant in clinical practice: use of an electronic data registry.
- Novel therapies for sarcoidosis.
- Etanercept for refractory ocular sarcoidosis: results of a double-blind randomized trial.
- Capecitabine plus paclitaxel as front-line combination therapy for metastatic breast Cancer: a multicenter phase II study.
- Increased rate of Brain metastasis with trastuzumab therapy not associated with impaired survival.
- The variability of sarcoidosis: can we predict it?
- Role of Liver function tests in detecting methotrexate-induced Liver damage in sarcoidosis.
- Therapy for extrapulmonary sarcoidosis.
- Thalidomide for Chronic sarcoidosis.
- Raloxifene is associated with less side effects than tamoxifen in women with early breast Cancer: a questionnaire study from one physician's practice.
- CD44 associates with EGFR and erbB2 in metastasizing mammary carcinoma Cells.
- Plasma membrane phosphotyrosine, Her2-NEU, and epidermal growth factor receptor in human breast Cancer. A comparative study.
- Sleep apnea in sarcoidosis.
- Quantitation of vascular endothelial growth factor mRNA levels in human Breast tumors and metastatic lymph nodes.
- Diagnosis and management of neurological sarcoidosis.
- Alternatives to corticosteroids in the treatment of sarcoidosis.
- Predicting respiratory failure in sarcoidosis patients.
- Steroid-sparing alternative treatments for sarcoidosis.
- Prevalence of digital clubbing in bronchogenic Carcinoma by a new digital index.
- Treatment of sarcoidosis with corticosteroids: who is going to relapse and why?
- Vascularity of proliferative breast disease and Carcinoma in situ correlates with histological features.
- Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast Cancer.
- Infliximab for chronic cutaneous sarcoidosis: a subset Analysis from a double-blind randomized clinical trial.
- Diagnosis and management of spinal cord sarcoidosis.
- Defining the clinical outcome status (COS) in sarcoidosis: results of WASOG Task Force.
- Fatigue in sarcoidosis: American versus Dutch patients.
- Inhaled iloprost for sarcoidosis associated pulmonary hypertension.
- Upper airway. 4: Sarcoidosis of the upper respiratory tract (SURT).
- Inhibitors of tumor necrosis factor (TNF) in sarcoidosis: who, what, and how to use them.
- HER-2/neu expression in primary and metastatic breast Cancer.
- Chronic facial sarcoidosis including lupus pernio: clinical description and proposed scoring Systems.
- Pulmonary hypertension in sarcoidosis.
- Newer therapies for cutaneous sarcoidosis: the role of thalidomide and other agents.
- Infliximab in Chronic ocular inflammation.
- Impact of metastatic estrogen receptor and progesterone receptor status on survival.
- Fungal infections as a complication of therapy for sarcoidosis.
- Leflunomide for Chronic sarcoidosis.
- Can persistent tumor necrosis factor release lead to refractory sarcoidosis?
- Use of fluticasone in acute symptomatic pulmonary sarcoidosis.
- Bilateral synchronous breast Cancer and HER-2/neu overexpression.
- Overexpression of transforming growth factor-alpha and epidermal growth factor-receptor in idiopathic pulmonary fibrosis.
- A clinical approach to the use of methotrexate for sarcoidosis.
- The risk of premature menopause induced by chemotherapy for early breast Cancer.
- New treatment for sarcoidosis: where''s the proof?
- The effect of estrogen usage on the subsequent hormone receptor status of primary breast Cancer.
- Methotrexate is steroid sparing in acute sarcoidosis: results of a double blind, randomized trial.
- Bilateral synchronous breast Cancer: mode of detection and comparison of histologic features between the 2 breasts.
- Cyclin D1, retinoblastoma, p53, and Her2/neu protein expression in preinvasive Breast pathologies: correlation with vascularity.
- Infliximab for refractory sarcoidosis.
- Combination therapy for sarcoidosis.
- Breast disease in sarcoidosis.
- Pulmonary lymphangitic metastasis from breast Cancer. Lymphocytic alveolitis is associated with favorable prognosis.
- c-myc, c-erbB-2, and Ki-67 expression in normal breast tissue and in invasive and noninvasive breast Carcinoma.
- Use of intermittent, intravenous cyclophosphamide for idiopathic pulmonary fibrosis.
- Increased tyrosine protein kinase activity in hairy Cell and monocytic leukemias.
- An inhibitor of tumor necrosis factor found in pleural effusions.
- The effect of Cancer and chemotherapy on monocyte function.
- Crackles in interstitial lung Disease. Comparison of sarcoidosis and fibrosing alveolitis.
- The effect of corticosteroid or methotrexate therapy on Lung lymphocytes and macrophages in sarcoidosis.
- Release of tumor necrosis factor by alveolar macrophages of patients with sarcoidosis.
- The use of low dose methotrexate in refractory sarcoidosis.
- Bleomycin causes alveolar macrophages from cigarette smokers to release hydrogen peroxide.
- Isolation of functionally active pleural macrophages.
- Marrow granulomas in coal workers' pneumoconiosis. A histologic study with elemental Analysis.
- Spontaneous hydrogen peroxide release from alveolar macrophages of patients with active sarcoidosis: comparison with cigarette smokers.
- The Anemia of sarcoidosis.
- Enzymatic and immunohistochemical evaluation of tyrosine phosphorylation in breast Cancer specimens.
- Increased phosphotyrosine in breast Cancer tissue is associated with a worse prognosis.
- Accuracy of Serial PET-CT Imaging in Systemic Sarcoidosis.
- Prolonged use of methotrexate for sarcoidosis.
- Paranoid psychosis due to neurosarcoidosis.
Schools
University Of Cincinnati College Of Medicine
University Cincinnati Hospital
Procedures Preformed
- Thoracentesis
Conditions Treated
- Anal and Rectal Cancer
- Anemia
- Basal Cell Carcinoma
- Bladder Cancer
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
Awards
- Meaningful Use Stage 1 Certification
- Fellow (FACP)
- Top MD
Education
-
University Hospital - University of Cincinnati College of Medicine -
University of Cincinnati College of Medicine
Hospital
-
Christ Hospital -
University of Cincinnati Medical Center
Drug Facts
| NPI NUMBER | 1447244843 | |
| NPPES Provider LastName | LOWER | |
| NPPES Provider FirstName | ELYSE | |
| NPPES Provider ZIPCode | 452192103 | |
| NPPES Provider State | OH | |
| Specialty Description | Medical Oncology | |
| Total Claim Count | 2617.0 | |
| Distinct Opioid Count | 2.0 | |
| Opioid Claim Count | 138.0 | |
| Percent Opioid Claims | 5.27 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1447244843 |
| Last Name Of The Provider | LOWER |
| First Name Of The Provider | ELYSE |
| View All |
Similar Doctors
|
|
Dr. Ehsan Malek, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Philip D. Leming, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Brian A. Mannion, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Edward B. Silberstein, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. James H. Essell, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jamie K. Waselenko, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Suzanne M. Partridge, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Luckson Mathieu, MD
This Doctor is OpenDoctor Recommended.
|